Scandinavian Real Heart AB (Realheart) (FN Stockhom:HEART), a designer and developer of a total artificial heart (TAH) for implantation in patients with life-threatening heart failure, announced on Tuesday that it has initiated the process of recruiting a new chief financial officer (CFO).
Current CFO, Andreas Hultdin, will resign from the company on 31 July 2022, but will stay on to support the company until a new CFO is appointed. in place.
According to the company, Hultdin has commitments outside of Realheart and cannot extend his involvement,
Legault Named Chairman and Board Member at Egle Therapeutics
XNK Therapeutics names new director
Bradrick Named to Spectrum Pharmaceuticals Board of Directors